Evon Medics
Ellicott City, Maryland
- Digital therapeutics
- Seed
- Alzheimer's and dementia
Evon Medics is a neurotechnology company developing medical devices and digital therapeutics to support brain health and address neurological conditions. Its technologies use olfactory stimulation and brain-training programs for applications including cognitive decline, substance use disorders, and chronic pain.
- RaisedTotal raised
- $23.1M
- Latest roundLatest priced round
- Seed
- Investors
- 3
- Employees
- 11–50
reccy insights
On September 2, 2026, Evon Medics announced that MemoryDriver would relaunch on September 15 with a national “Beat the Clock” navigation challenge. The company describes MemoryDriver as a free navigation-based cognitive-training app, extending its work beyond clinical and therapeutic products into a consumer-facing brain-training experience. On March 25, 2026, Evon Medics publicized COAT-related data reporting improved cognition and changes in gray matter in brain regions associated with Alzheimer’s disease. These are company-reported findings and do not, on their own, establish clinical effectiveness. Earlier milestones include four disclosed grants between April 2021 and May 2023 totaling $11,620,064, with support associated with the National Institute on Aging, the National Institute on Drug Abuse, and the National Institute of Neurological Disorders and Stroke. In September 2022, co-founder Dr. Evaristus Nwulia was appointed director and principal investigator of the NeuroTech Harbor Technology Accelerator. The available company updates emphasize product development and research; no partnerships or awards are identified in the available profile information.
Written by reccy's AI from company sites, press and funding records · updated Oct 2026
What makes Evon Medics distinct
- 01Develops olfactory-based brain stimulation and training technologies grounded in neuroscience research.
- 02Targets applications including Alzheimer’s disease, substance use disorders, and chronic pain.
- 03Combines medical devices with digital therapeutics and remote patient-management capabilities.
- 04Its COAT clinical study reported promising cognitive and brain-health outcomes in people with mild cognitive impairment.
- 05MemoryDriver is presented as the company’s first commercially available product.
Technology & products6
- COAT™ (Computerized Olfactory Adaptive Training)
A non-invasive, home-based olfactory training system for cognitive support in people with mild cognitive impairment and early Alzheimer’s disease.
- Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)
A home-based chemosensory training system under development for substance use disorder and chronic pain applications.
- MemoryDriver™
A brain-training application with navigation-based exercises intended to support memory, spatial navigation, focus, and cognitive performance.
+ 3 more: EDITOR, CBOT-P, Evon Medics Rapid Smell Test (EMRAST)
Recent updates2
- Sep 2, 2026Product launch
Evon Medics announced a September 15, 2026 relaunch of MemoryDriver, a free cognitive-training navigation app, alongside a national navigation competition.
prnewswire.com - Feb 2026Product launch
Evon Medics Officially Launches MemoryDriver™ 1.0
youtu.be
Funding
- GrantMay 2023$2.9M
- GrantSep 2022
- GrantMay 2022$2.8MLed by National Institute on Drug Abuse (NIDA)
Similar companies
About Evon Medics
- Products
- COAT™ (Computerized Olfactory Adaptive Training), Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT), MemoryDriver™, EDITOR, CBOT-P, Evon Medics Rapid Smell Test (EMRAST)
- Leadership
- Charles Nwaokobia, Chief Operating Officer
- Focus areas
- Neurotechnology, neurology, brain health, digital therapeutics, medical devices, alzheimer s disease, cognitive training, remote patient monitoring
- Headquarters
- Ellicott City, Maryland
- Employees
- 11–50
- Patents granted
- 5
- Trademarks
- 3